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and/or increase the likelihood of radiation-induced toxicities. 
Prospective trials have shown that RTQA variations have a 
significant impact on the primary study end-point and could 
bias the analysis of the trial results[6]. A large prospective 
phase III (i.e. TROG 02.02) trial showed indisputably that 
poor radiotherapy resulted in suboptimal patient’s outcomes. 
Moreover, the impact of poor quality radiotherapy delivery 
exceeded greatly the benefit of chemotherapy, thus biasing 
the primary end-point of this study. This large Australian trial 
provided a contemporary benchmark that future studies will 
need to exceed. Other specific consideration for RTQA in 
trials includes, but is not limited to, education of the 
accruing sites in RT-trial guidelines, promotion of consistency 
between centers and estimation of inter-patient and inter-
institutional variations. Additionally, global cooperation is 
essential in the environment of common and rare cancers 
alike, in order to be able to create sufficiently large patient 
data sets within a reasonable recruitment period. This 
cooperation is not without issues and recently the need to 
have harmonized RTQA procedures has been strongly 
advocated by the Global Harmonisation Group. Ensuring RT 
compliance with protocol guidelines involves however 
gradually more resources-intensive procedures which are also 
labor intensive and are not cost-neutral. This will 
consequentially have a significant impact on the overall study 
budget. There are suggestion that QA programs are however 
cost-effective. This financial investment is of paramount 
importance, as non-adherence to protocol-specified RT 
requirements in prospective trials is very frequent. The 
European Organisation for the Research and Treatment of 
Cancer (EORTC) Radiation Oncology Group started to 
implement RTQA strategies in the 1980s, including on how to 
write a protocol for RT trials, defining RTQA procedures (such 
as benchmark case, dummy run and complex treatment 
dosimetry checks), assuring prospective individual case 
review feasibility and implementing an electronic data-
exchange platform.  
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A trial protocol with clearly established delineation 
guidelines and dose-volume parameters is key to all RTQA. 
Acceptable and unacceptable variations thereof should be 
defined before the trial starts as these are the standards to 
which all RTQA data collected will be compared. The 
experience so far has been addressed by the previous two 
speakers. Dr. Miles presented the RTQA procedures in clinical 
trials, differentiating between pre-accrual and during accrual 
tasks. Thereafter, Dr. Weber clearly showed that non 
adherence to protocol-specified RT requirements is 
associated with reduced survival, local control and 
potentially increased toxicity. Thus, it can be concluded that 
clinical trial groups have established RTQA procedures and 
conformance to these procedures strengthen the trial results.  
In this talk the remaining issues that need to be solved will 
be addressed. These issues can be separated in:  
1. How can we further optimising the current RTQA 
2. How should we include new imaging and treatment 
modalities in our RTQA program?  
The first part of the talk will address several initiatives to 
further optimise current RTQA procedures. As we have 
learned from past RTQA experience, currently the individual 
case reviews (ICRs) are the most common source of variations 
from trial protocols. ICR variation is also the most important 
RTQA factor affecting trial outcome. Thus, a transition is 
needed from retrospective ICRs to timely, full prospective 
ICRs. Also, with the further advancement of tailored 
treatments for small subgroups of patients there is a growing 
need for intergroup trials to increase the accrual rates when 
conducting trials for such patient groups. These changes 
place new requirements on multiple parts in the RTQA 
procedure:  
- Standardisation of RTQA across various trial groups. The 
Global Harmonisation Group initiative. 
- Standardisation of protocol requirements with clear 
definitions of acceptable and unacceptable variations. 
- Standardisation of OAR and target naming conventions. 
- Automated upload of RTQA data from institutions to the 
RTQA review organisation, including anonymisation software, 
use of Dicom standards. 
- Metrics and software tools to automatically evaluate image 
quality, delineations and treatment plans.  
The second part of the talk will address the ideas of including 
new diagnostic, treatment and evaluation modalities and 
techniques in RTQA programs. Examples will be shown of 
RTQA trial procedures for breathing correlated 4D-CT, 4D 
PET-CT, MRI and CBCT currently in use or under 
development.  
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Purpose or Objective: There is conclusive evidence that 
radiotherapy (RT) can initiate an immune response. 
Previously, we have shown that addition of L19-IL2 to RT was 
able to increase the immune response and that this 
combination therapy resulted in a long-lasting synergistic 
anti-tumor effect. Here we hypothesize that tumor cells 
outside the radiation field will also be eliminated by this 
combination treatment (abscopal effect) and that tumors 
cannot be formed again after re-challenging cured animals 
(memory effect). 
 
Material and Methods: Immunocompetent Balb/c mice were 
subcutaneously injected with syngeneic colorectal C51 cells 
in both flanks at different days. Primary tumors were 
irradiated upon a volume of 200 mm³ (15Gy or 5x2Gy) 
followed by PBS or L19-IL2 administration and the growth of 
the secondary non-irradiated tumors was monitored. Cured 
mice were reinjected after 150 days with C51 tumor cells and 
tumor uptake was assessed. Several immunological 
parameters in blood, tumors, lymph nodes and spleens were 
investigated in both experiments. 
 
Results: RT+L19-IL2 was able to cure 100% of primary tumors 
and was associated with an increased percentage of CD8+ T 
cells inside these irradiated tumors. When a single RT dose of 
15Gy was combined with L19-IL2, 20% of the non-irradiated 
secondary tumors were cured. Interestingly, the non-
irradiated tumors of mice treated with 15Gy+L19-IL2 showed 
a significant (p<0.01) increased percentage of CD4+ T cells 
compared to irradiated tumors. Fractionated radiotherapy 
combined with L19-IL2 caused a significant (p<0.01) growth 
delay in the non-irradiated tumors, however no secondary 
tumors were cured. Immunological analysis revealed an 
increase in PD-1 expression on T cells infiltrating these 
tumors, suggesting a more regulatory phenotype after 
fractionated radiotherapy compared with one single RT dose. 
New C51 tumors were not able to form in cured mice whereas 
100% of the age-matched control mice formed tumors that 
reached established end-points within 17 days. Splenic T cells 
of these cured mice were associated with a high expression 
of CD127. 
 
Conclusion: Our data show that RT+L19-IL2 causes anti-tumor 
immune effects outside the radiation field and this effect is 
associated with an increase of CD4+ T cells. Cured mice are 
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not able to form new tumors and have high expression of 
CD127 on their T cells, a marker for immunological memory. 
This new treatment will be further investigated in a Phase I 
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Purpose or Objective: The novel combretastatin analogue, 
OXi4503, is a vascular disrupting agent (VDA) that has 
recently been shown to significantly enhance a stereotactic 
radiation treatment. This was achieved using an OXi4503 dose 
of 10 mg/kg combined with a stereotactic treatment of 3 x 
15 Gy. The current study was undertaken to determine the 
OXi4503 dose dependency when using different stereotactic 
radiation dose schedules. 
 
Material and Methods: A C3H mammary carcinoma grown in 
the right rear foot of female CDF1 mice was used in all 
experiments. Treatments were performed in restrained non-
anaesthetised animals when tumours had reached 200 cubic 
mm in size. Tumours were locally irradiated (230 kV x-rays) 
with 3 fractions of radiation varying from 5-20 Gy (each 
fraction given with an interval of 2-3 days over a one week 
period). OXi4503 was dissolved in saline prior to each 
experiment; once prepared it was kept cold and protected 
from light. Various doses (5-25 mg/kg) were intraperitoneally 
injected into mice 1-hour after each irradiation treatment. 
Three days after the final irradiation the tumours were 
subjected to a clamped top-up dose which involved giving 
graded radiation doses with the tumour bearing leg clamped 
for 5 minutes before and during irradiation. The percentage 
of mice in each treatment group showing local tumour 
control 90 days after irradiating was then recorded. Following 
logit analysis of the clamped top-up radiation dose response 
curves, the TCD50 values (radiation dose to control 50% of 
tumours) were estimated. A Chi-squared test (p<0.05) was 
used to determine significant differences between the TCD50 
values. 
 
Results: The clamped top-up TCD50 values (with 95% 
confidence intervals) obtained following irradiation with 3 
treatments of 10, 15 or 20 Gy were found to be 42 Gy (38-
47), 30 Gy (23-39), and 0.8 Gy (0.3-2.3), respectively. A plot 
of the TCD50 values against the stereotactic doses gave rise 
to a linear response (slope = -4.1; correlation coefficient = 
0.97). OXi4503 significantly decreased the clamped radiation 
top-up TDC50 values and this affect appeared to be 
independent of both the ambient radiation dose applied with 
each of the 3 fractions and the VDA dose; the curve showing 
the TCD50 values against stereotactic radiation dose was 
similar to that for radiation alone (slope = -4.3; correlation 
coefficient = 0.94), but the radiation + OXi4503 curve was 
some 15 Gy lower than the radiation only curve. 
 
Conclusion: OXi4503 is an effective agent for enhancing a 
stereotactic radiation treatment. But, the enhanced response 
appeared to be a simple additive effect independent of both 
the radiation dose applied with each fraction and the VDA 
dose used. 
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Purpose or Objective: Hypoxia is a common feature of solid 
tumors. Conventional treatments such as chemo- and 
radiotherapy (RT) are less effective against hypoxic tumor 
cells. Hypoxia-activated prodrugs (HAPs) are specifically 
activated in hypoxia to target hypoxic cells as well as 
adjacent oxygenated tumor cells via their bystander effect. 
DTP-006 is a newly synthesized nitroaromatic HAP with highly 
favorable properties: 1) activation under hypoxia, 2) high 
bystander effect, 3) excellent aqueous solubility, 4) murine 
oral bioavailability and 5) no off-mechanism activation by 
human aerobic reductases NQO1 and AKR1C3. Here we show 
the effects of DTP-006 on tumor cell viability, spheroid 
growth and radiation resistant tumor cells in vivo, and assess 
its pharmacokinetics and oral bioavailability in mice. 
 
Material and Methods: The one-electron reduction potential 
(E1) of DTP-006 was determined by pulse and steady state 
radiolysis. IC50 viability ratios were assessed in 2D cell 
culture exposed to normoxic or anoxic (≤0.0 2% O2) 
conditions. H460 multicellular layers (MCLs) under aerobic 
(5% CO2, 95% O2) or anoxic (5% CO2, 95% N2) conditions were 
incubated with DTP-006 for 5 h after which cells were plated 
for clonogenic survival. H460 spheroids were incubated with 
DTP-006 upon confirmation of a hypoxic core. NIH-III mice 
bearing H460 tumors received a single i.p. dose of DTP-006 
(781 mg/kg) after irradiation (10 Gy) of tumors. 18 h later 
tumors were excised and single cell suspensions were 
generated and plated for clonogenic survival. Tumor-free 
female NIH-III mice received a single i.v. or oral dose of DTP-
006 (383 mg/kg). Terminal blood samples collected at time 
points via cardiocentesis were analyzed by LC/MS/MS. Plasma 
half-life (T1/2) and absolute oral bioavailability (Fabs) were 
calculated. 
 
Results: DTP-006 has an E1 value of -351 mV, indicating 
strong oxygen inhibition of nitro radical formation. IC50 were 
lower in anoxia than normoxia by factors of 203 (MDA-MB-
468), 55 (C33A), and 20 (HCT116). In a H460 MCL clonogenic 
assay, 100 µM DTP-006 caused 99% cell kill under anoxia but 
exhibited no aerobic cell kill. It caused a concentration-
dependent growth delay in spheroids, where 250 µM 
completely halted growth. A single dose of DTP-006 caused a 
significant loss of clonogenicity when combined with RT in an 
in vivo excision assay (log cell kill 2.35 relative to control). 
T1/2 after oral administration was 0.82 h and bioavailability 
was 47%. 
 
Conclusion: DTP-006 kills tumor cells only in severe hypoxic 
conditions in vitro, reduces growth of tumor cell spheroids, 
and sterilizes radiation resistant tumor cells in vivo. It has 
clinically relevant bioavailability after oral administration. As 
such, DTP-006 is a promising new HAP with potentially 
favorable properties for clinical use. Further studies to 
determine the antitumor effects of DTP-006 as a 
monotherapy and in combination with RT in several 
preclinical tumor models are ongoing. 
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